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Objective. To estimate the minimum clinically important difference (MCID) for several pain measures obtained from the
Brief Pain Inventory (BPI) for patients with fibromyalgia.
Methods. Data were pooled across 12-week treatment periods from 4 randomized, double-blind, placebo-controlled
studies designed to evaluate the safety and efficacy of duloxetine for the treatment of fibromyalgia. Each study enrolled
subjects with American College of Rheumatology–defined fibromyalgia who presented with moderate to severe pain. The
MCIDs for the BPI average pain item score and the BPI severity score (the mean of the BPI pain scale values: right now,
average, least, and worst) were estimated by anchoring against the Patient’s Global Impressions of Improvement scale.
Results. The anchor-based MCIDs for the BPI average pain item and severity scores were 2.1 and 2.2 points, respectively.
These MCIDs correspond to 32.3% and 34.2% reductions from baseline in scores.
Conclusion. In these analyses, the MCIDs for several pain measures obtained from the BPI were similar (2 points) and
corresponded to a 30–35% improvement from baseline to end point. These findings may be beneficial for use in designing
clinical trials in which the BPI is used to evaluate improvements in pain severity.
INTRODUCTION
Pain throughout the body is generally considered the most
debilitating of the symptoms experienced by patients with
fibromyalgia. Fibromyalgia experts and patients with fi-
bromyalgia rate pain as the most important symptom do-
main to evaluate in clinical trials (1). The scales used to
measure and monitor pain levels vary and include visual
analog scales (VAS) for pain (2), the McGill Pain Question-
naire (3), the Fibromyalgia Impact Questionnaire (FIQ)
pain item (4), various numerical rating scales (often re-
corded in diaries), and the Brief Pain Inventory (BPI) (5).
To date, 3 drugs (duloxetine, pregabalin, and milnacip-
ran) have been approved by the Food and Drug Adminis-
tration for the management of fibromyalgia. In clinical
trials of duloxetine, a serotonin and norepinephrine re-
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uptake inhibitor (SNRI), the BPI average pain item score
was used as the primary measure of pain severity in 3
phase III, multicenter, placebo-controlled trials (6–8),
while the FIQ pain item score was used in an earlier
placebo-controlled, phase II feasibility trial (9). With the
SNRI milnacipran, a VAS was used to measure pain levels
in 2 clinical trials (10,11). In studies of the anticonvulsant
pregabalin, a VAS was used to measure pain in 1 trial (12)
and an 11-point numerical rating scale was used in an-
other trial (13).
To appropriately interpret the results from any pain
scale, regardless of which specific scale is utilized, the
minimum clinically important difference (MCID) (14)
must be determined for the respective scale. The MCID is
the smallest level of change in a given scale associated
with a clinically meaningful improvement in a patient.
The MCID value is unique to each pain scale and is a
quality that should be determined as part of the scale’s
validation process. Additionally, MCIDs may differ for a
given scale based on the type (e.g., chronic versus acute)
or location (e.g., low back versus headache) of the pain
(15,16).
There are 2 main types of MCIDs: group and individual
(17). Group MCIDs focus on an average minimum re-
sponse, such as mean change, across patients, and are
important for study design and planning. Individual
MCIDs provide information about response at the indi-
vidual level and may be represented, for example, by a
cutoff value or percent change. Individual MCIDs, while
also potentially useful in study design and planning, pro-
vide the clinician with a means of determining clinically
significant responses at the patient level.
There are a variety of approaches for determining both
group and individual MCIDs (15–18). Copay et al (16)
have placed the various methodologies into 2 categories:
anchor-based methods and distribution-based methods.
Anchor-based methods compare the changes in patient-
rated outcomes to an anchor, which is usually a patient-
rated outcome such as a global assessment scale; the
Patient’s Global Impressions of Improvement (PGI-I) (19)
is one example. Moreover, there are several variations of
anchor-based methodology (16). Distribution-based meth-
ods also have a variety of approaches to estimate the
MCID, including use of the SEM, SD, and effect sizes. The
merits and limitations for both anchor- and distribution-
based methods have been reviewed previously (15).
In this analysis, we have pooled data from 4 clinical
trials designed to assess the efficacy of duloxetine for the
treatment of pain associated with fibromyalgia, and we
estimated the group MCID for the BPI average pain item
score and the BPI pain severity score using anchor-based
methodology. Estimation of the group MCID for these
measures will provide useful information for future clini-
cal trial design and interpretation using these pain mea-
sures (15).
PATIENTS AND METHODS
Study design. Pain data were pooled from 4 random-
ized, double-blind, placebo-controlled trials of duloxetine
for the treatment of fibromyalgia (6–9). Data were inte-
grated from the entire 12-week treatment phase of 2 stud-
ies and from the initial 3-month treatment periods of 2
1-year studies (Table 1). In study 3, patients were ran-
domly assigned to fixed dosages of duloxetine: 20 mg/day
(n  79), 60 mg/day (n  150), 120 mg/day (n  147), or
placebo (n  144) for the first 15 weeks. In study 4, pa-
tients were randomly assigned to 23 weeks of duloxetine
treatment including 8 weeks at 60 mg/day, followed by
15 weeks of duloxetine continuing at 60 mg/day or in-
creasing to 120 mg/day depending on clinical response
and tolerability (n  162) or placebo (n  168). Although
patients in both studies 3 and 4 could be treated for up to
1 year, data were only taken from the first 3 months to
ensure that MCID assessments were based on patient out-
comes obtained from similar treatment durations.
All patients provided written informed consent, and
the institutional review board for each clinical study site
approved the protocol, which was developed in accor-
dance with the ethical standards of Good Clinical Practice
and the Declaration of Helsinki. Further details about the
methods can be found in the published reports for each of
the 4 studies (6–9).
Patient population. Patients were ages 18 years, male
or female outpatients (only women included in study 2),
and with or without major depressive disorder (MDD). All
patients met the criteria for fibromyalgia as defined by
the American College of Rheumatology (20). Patients in
all studies were also required to have a score of 4 on
either the pain intensity item of the FIQ (study 1), or
the average pain item of the BPI (studies 2–4). Patients
were excluded from each study if they had any current
primary psychiatric diagnosis other than MDD: had a pos-
itive urine drug screen for any substances of abuse; were
taking concomitant medications (such as antidepressants,
anticonvulsants, and opioids) that may interfere with pain
evaluations; were a serious suicidal risk; or had a serious
medical illness. Details of inclusion and exclusion criteria
can be found in the published studies (6–9).
MCID assessments. The modified short form of the BPI
was used in these analyses to determine the MCID (5). The
BPI is a patient self-reported 11-point numerical rating
scale that measures the severity of pain and the interfer-
ence of pain on function. There are 4 questions assessing
worst pain, least pain, average pain, and pain right now.
The scores range from 0 (no pain) to 10 (pain as severe as
you can imagine). The MCID was determined for the BPI
average pain item score and for the BPI severity score,
which is the mean of the BPI pain severity items, defined
as worst pain, least pain, average pain, and pain right now.
These 2 BPI scores are most often used as primary mea-
sures of average pain severity. The MCIDs (i.e., BPI average
pain item score and BPI severity score) were determined
by anchoring against the PGI-I scale (19). The PGI-I is a
patient-rated 7-category ordinal assessment that measures
the patient’s general level of improvement and is scored as
follows: 1  very much better, 2  much better, 3  a little
better, 4  no change, 5  a little worse, 6  much worse,
and 7  very much worse.
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The PGI-I–based group MCID was calculated as the dif-
ference in mean change from baseline to end point in the
BPI item scores between patients considered “clinically
stable” and patients demonstrating “minimal clinically
relevant improvement.” “Clinically stable” was defined
as those patients having an end point PGI-I score of 4
(no change). “Minimal clinically relevant improvement”
was defined as those patients having an end point PGI-I
score of 2 (much better). Patients reporting a PGI-I score of
3 (a little better) at end point were not considered to have
achieved clinically relative improvement (21). All patients
with at least 1 postbaseline BPI observation were included
in the calculation of the MCID, irrespective of treatment
assignment. The MCIDs for both the BPI average pain score
and the BPI severity score were also determined for sub-
groups, including patients with or without MDD (22,23), to
determine whether the presence of comorbid depression
affected the MCIDs. The definition of MDD was defined by
the Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition. To evaluate whether the presence of an
analgesic agent from duloxetine affected the MCIDs, the
MCIDs for the same pain scores were also determined for
patients taking placebo and duloxetine.
The clinically important difference (CID) was also esti-
mated for the BPI average pain score and the BPI severity
score. The CID is the level of change in a scale associated
with any level of clinically significant improvement in
patients (21), and is a value that may be helpful in aspects
of clinical trial design (24). In our determination of the
group CID based on PGI-I anchoring, patients having an
end point PGI-I score of either 1 (very much better) or 2
(much better) were used to identify those patients who had
an overall clinically important difference.
Statistical analysis. Patients with a baseline and at least
1 postbaseline measurement were included in the MCID
analyses. The baseline score was defined as the last non-
missing observation prior to receiving treatment. The end
point observation was defined as the last nonmissing ob-
servation within the 3-month treatment period. The MCID
was calculated as the difference in the unadjusted mean
change in the BPI scores between the “stable” group and
the group with “minimal clinically relevant improved” for
each measure. The MCID was also expressed as a percent-
age reduction from the mean baseline scores for the stable
and improved groups of each measure. To assess any im-
pact of treatment effect or baseline MDD status on the
MCIDs, subgroup analyses were also conducted. Similar to
the MCID, the CID was estimated as the difference in the
unadjusted mean change in the BPI scores between the
“stable” group and the group with “clinically relevant
improvement” (PGI-I end point score of 1 or 2).
RESULTS
The majority of the patients included in the analyses were
women (94.9%) and white (87.5%), with a mean age of
50.3 years (Table 2). The degree of pain was considered
moderately severe as indicated by a score of 6.5 on the BPI
average pain item. The number of patients rating them-








Study 1: phase II 12 DLX (120 mg)  104 FIQ total†
Proof of concept (9) PBO  103 FIQ pain item
Study 2: phase III fixed 12 DLX (60 mg)  118 BPI average pain item
Dose pivotal (females only) (6) DLX (120 mg)  116
PBO  120
Study 3: phase III 28/ DLX (20 mg)  79 BPI average pain item
Fixed dose pivotal (7) 28-week extension‡ DLX (60 mg)  150 PGI-I at 15 weeks
DLX (120 mg)  147
PBO  144
Study 4: phase III 27/ DLX (60–120 mg)  162 BPI average pain item
Flexible dose supportive (8) 29-week extension‡ PBO  168 PGI-I at 27 weeks
* MCID  minimum clinically important difference; DLX  duloxetine; FIQ  Fibromyalgia Impact Questionnaire; PBO  placebo; BPI  Brief Pain
Inventory; PGI-I  Patient’s Global Impressions of Improvement.
† BPI also measured in study 1.
‡ Used data from initial 3 months of treatment.












African descent 33 (2.3)
Other 18 (1.2)
BPI average pain score, mean  SD 6.5  1.5
CGI-S, mean  SD 4.2  1.0
PGI-S, mean  SD‡ 3.9  1.4
* BPI  Brief Pain Inventory; CGI-S  Clinical Global Impressions
of Severity; PGI-S  Patient’s Global Impressions of Severity.
† Numbers may vary slightly due to missing data.
‡ PGI-S at baseline collected only in studies 3 and 4.
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selves as “very much better” (PGI-I of 1) was 142, whereas
249 patients rated themselves as “much better” (PGI-I of 2).
Table 3 shows the analyses of MCIDs for the BPI average
pain score and BPI severity score. The MCIDs for both
scores using the PGI-I as the anchor were an improvement
of 2.1 points. The MCIDs expressed as percentage im-
provement from baseline were 32.3% for the BPI average
pain score and 34.2% for the BPI severity score.
The subgroup results were similar to the main results in
that all MCIDs were between 30% and 35% improvement
on the BPI pain scores (Figure 1). The MCIDs for both the
BPI average pain scores and BPI severity scores were iden-
tical for the placebo and duloxetine when the PGI-I was
used as the anchor. The patients without MDD had a
similar MCID to patients with MDD (1–3%) using the
PGI-I as anchor for both the BPI average pain and BPI
severity scores.
The CID was also analyzed using the PGI-I as the anchor.
The CID for the BPI average pain score was 2.82, which
corresponds to a 43.4% improvement from baseline. The
CID for the BPI severity score was 2.79 (36.9% improve-
ment). The CID on the BPI average pain score was an
improvement of 2.56 (40.0%) for the placebo group and
2.67 (41.0%) for the duloxetine group. The CID for the
BPI severity score was 2.51 (40.4%) for the placebo group
and 2.76 (43.5%) for the duloxetine group. The CID for the
BPI average pain score was 2.61 (40.8%) for patients with-
out MDD and 2.89 (42.8%) for patients with MDD. The CID
for the BPI severity score was 2.65 (42.7%) for patients
without MDD and 2.86 (43.2%) for patients with MDD.
DISCUSSION
In these analyses, the MCID for both the BPI average pain
score and BPI severity score averaged somewhat more than
a 2-point improvement for all patients with moderate to
severe pain that met criteria for the analyses as well as for
each of the subgroups. Moreover, the MCIDs, as expressed
by the percentage improvement from baseline, were all
between 30% and 35%. The CIDs ranged from 40–44%.
The results of these analyses are similar to MCIDs cal-
culated in other pain conditions, i.e., approximately a
2-point improvement on a scale of 0 (no pain) to 10 (most
severe pain). A study by Farrar and colleagues analyzed
10 trials of pregabalin for various chronic pain conditions
to determine clinical importance of changes on a numeri-
cal rating scale similar to the BPI (21). They used the PGI-I
as the anchor in these analyses. They found that a PGI-I
improvement score of 2 (much better) resulted in an im-
provement of between 2.2 and 3.2 points on the rating
scale, depending on the study. The percentage of improve-
ment varied from 35–55%. These estimates are somewhat
greater than what we found in our study; however, one
should keep in mind that variables such as different pa-
tient and/or study populations, pain types, and study de-
sign may influence MCIDs.
Of important note, the MCID estimates present in this
study were adjusted for the increased sensitivity to change
possessed by the BPI item scores as compared with the
PGI-I, which may be attributed to the BPI items’ broader
response profile. By adjusting the MCID estimates through
subtraction of the amount of improvement in the BPI
scores associated with “no change” in the PGI-I from that
associated with PGI-I indicated as “much better,” a more
precise estimate of the MCID is obtained. Had this adjust-
ment not been instituted, the MCIDs for the BPI average
pain score and severity score would be 2.8 and 2.7 points,
respectively. This corresponds to overestimates of the
MCIDs of 31.6% and 24.5%, respectively. Such impreci-
sion may have considerable impact on the design of pain
Table 3. Estimation of mean changes in BPI average pain and BPI severity scores*






mean  SEM MCID†
Average pain PGI-I improved 249 6.45  1.59 3.70  2.02 2.75  0.12 2.09 (32.3)
PGI-I stable 240 6.50  1.43 5.85  1.97 0.65  0.12
Severity PGI-I improved 249 6.29  1.58 3.60  1.99 2.70  0.11 2.16 (34.2)
PGI-I stable 240 6.35  1.55 5.81  1.90 0.54  0.11
* BPI  Brief Pain Inventory; LS  least squares; MCID  minimum clinically important difference; PGI-I  Patient’s Global Impressions of Improvement.
† Expressed as score reduction (PGI-I improved  PGI-I stable) and percent reduction from baseline.
Figure 1. Minimum clinically important differences (MCIDs) by
subgroup using the Patient’s Global Impressions of Improvement
as anchor. Percentages represent the percentage of improvement
from baseline in the Brief Pain Inventory scores. Placebo (PBO):
n  124 for stable, n  71 for improved. Duloxetine (DLX): n 
116 for stable, n  178 for improved. Non–major depressive
disorder (MDD): n  175 for stable, n  183 for improved. MDD:
n  65 for stable, n  66 for improved.
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trials, particularly with consideration to sample size and
power.
In reviewing MCID estimates for other pain scales and in
other pain conditions, findings appear to be consistent
with those presented herein. To our knowledge, the BPI
has not been used to determine the MCID in fibromyalgia
or any other chronic pain state. However, a number of
similar numerical rating scales have been used to assess
the MCID. In a study of patients with low back pain, a
2-point improvement on a scale of 0–10 was calculated as
the MCID (25). Patients with neck pain exhibited an MCID
of 1.3 points on a 0–10 numerical rating scale for pain (26).
That study used a global rating scale that rated improve-
ment from 7 (a very great deal worse) to 0 (about the
same) to 7 (a very great deal better). Overall, and for a
variety of pain conditions, the MCID tends to be approxi-
mately a 2-point improvement on an 11-point scale.
Where other scales have been used, such as the VAS, the
amount of improvement is also quite comparable to our
study. For example, in a study of patients who have been
treated for chronic low back pain (27), the MCID was
found to be an 18-point improvement on a VAS back pain
measure (100-point scale). This would translate to a 1.8-
point improvement on a scale of 0–10; therefore, the
minimal amount of improvement considered to be clini-
cally important is comparable using the BPI or VAS. Sim-
ilar to our study, the mean score for the “unchanged”
group was subtracted from the mean score for those who
were “better” to determine the MCID. A variety of methods
have been used to determine the MCID in pain conditions.
The group MCID was evaluated using both distribution-
based and anchor-based methods in patients with neck
pain using the Northwick Park Neck Pain Questionnaire
(NPQ) (28). The main finding was that the MCID was a
25% reduction in the NPQ score with a global rating hav-
ing to be at least “better” (0  much worse, 1  worse, 2 
no change, 3  better, and 4  much better). Jordan et al
also used a mix of distribution-based and anchor-based
methodology to determine the individual MCID in patients
with low back pain (24). In that study, back pain was
assessed using the Roland-Morris Disability Questionnaire
(RMDQ). As above, the back pain had to be rated as better
on a global scale and the RMDQ score had to be improved
by 30% from baseline. These MCIDs that use different
methods, patient populations, and pain scales are, again,
comparable to the 30–35% improvement we observed in
our analyses of fibromyalgia pain using group MCID meth-
odology.
Farrar and colleagues have derived both group and in-
dividual MCIDs in patients with various pain conditions
(21,29). They found approximately a 2.5 point, or 35%,
improvement in pain on a 0–10 rating scale in patients
with fibromyalgia who had rated themselves as “much
improved” on the patient’s global impression of change
(21). This group-level finding is similar to the group MCID
observed in our analyses in patients with fibromyalgia.
The group CID of 2.8 points in the present study is
similar to the individual CID of 2.5 for BPI average pain
in a pooled analysis of patients with diabetic peripheral
neuropathic pain (3 studies) and fibromyalgia (2 studies)
treated with duloxetine or placebo (29). These results,
along with the previously mentioned studies, suggest that
MCIDs and/or CIDs will likely have very similar results if
assessed using either individual or group measurements.
The MCID estimates derived from subgroup assessments
based on MDD status and treatment assignment were vir-
tually identical (expressed as percentage improvement) to
the MCID for the overall study populations. Evaluations of
these subgroups were important to ensure that estimates of
MCIDs were not confounded by the presence of patients
with MDD, since a significant percentage of patients with
MDD report having painful physical symptoms (22,23),
and duloxetine has been shown to improve these symp-
toms in patients with MDD (30,31). Interestingly, patients
without MDD actually had a slightly higher MCID (ex-
pressed as a percentage) than did the patients with MDD,
although this difference was not clinically meaningful.
Several limitations should be considered when review-
ing this study. These were post hoc analyses from 4 du-
loxetine studies conducted using patient populations that
were very similar to one another; therefore, extrapolation
of our findings to other studies of patients with fibromy-
algia should be made with care. We used only anchor-
based methodology to determine the MCID, and it should
be noted that there could be subjectivity in how the values
of the anchor are mapped to clinical importance. Future
work could include determining the MCID using distri-
bution-based methodology and using tools that offer in-
creased sensitivity to patient-rated improvement com-
pared with the PGI-I, such as the Patient Acceptable
Symptom State (32), which identifies the symptom state
that patients consider as acceptable.
In general, there have been a number of alternate terms
used within the literature when referring to the concept of
the MCID for a given measure, and this can be further
complicated by similar, yet different, measures such as the
minimally clinically detectable difference. It is, therefore,
important that readers understand the concept underlying
the values discussed within the literature to ensure proper
use and application. Importantly, our anchor-based ap-
proach to determining the MCID is one of many available
methods for estimating this measure, and MCIDs obtained
from different methods may be variable. Strengths of this
work include the availability of a large patient population
for these analyses, as well as improved precision in MCID
estimates based on adjustments in sensitivity between the
outcomes of interest (the BPI items) and the global anchor
(the PGI-I score).
In conclusion, findings from these analyses suggest that
a 2-point improvement on the BPI average pain score and
BPI severity score, or a 30–35% improvement from base-
line to end point in both BPI scores, represents the MCID
for these items in fibromyalgia patients presenting with
moderate to severe pain.
AUTHOR CONTRIBUTIONS
All authors were involved in drafting the article or revising it
critically for important intellectual content, and all authors ap-
proved the final version to be submitted for publication. Dr. Mease
had full access to all of the data in the study and takes responsi-
bility for the integrity of the data and the accuracy of the data
analysis.
MCID for Fibromyalgia Pain 825
Study conception and design. Mease, Spaeth, Clauw, Arnold,
Bradley, Russell, Kajdasz, Chappell.
Acquisition of data. Mease, Spaeth, Russell, Kajdasz, Chappell.
Analysis and interpretation of data. Mease, Spaeth, Bradley,
Russell, Kajdasz, Walker, Chappell.
ROLE OF THE STUDY SPONSOR
Eli Lilly and Boehringer Ingelheim GmbH played a role in the
study design, collection and analysis of the data, and preparation
of the manuscript. Eli Lilly employees were involved in review of
the manuscript prior to submission for publication. Publication of
this article was not contingent upon approval by the study spon-
sors.
REFERENCES
1. Mease PJ, Clauw DJ, Arnold LM, Goldenberg DL, Witter J,
Williams DA, et al. Fibromyalgia syndrome. J Rheumatol
2005;32:2270–7.
2. DeLoach LJ, Higgins MS, Caplan AB, Stiff JL. The visual
analog scale in the immediate postoperative period: intra-
subject variability and correlation with a numeric scale.
Anesth Analg 1998;86:102–6.
3. Melzack R. The short-form McGill Pain Questionnaire. Pain
1987;30:191–7.
4. Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia im-
pact questionnaire: development and validation. J Rheumatol
1991;18:728–33.
5. Cleeland CS, Ryan KM. Pain assessment: global use of the
Brief Pain Inventory. Ann Acad Med Singapore 1994;23:
129–38.
6. Arnold LM, Rosen A, Pritchett YL, D’Souza DN, Goldstein
DJ, Iyengar S, et al. A randomized, double-blind, placebo-
controlled trial of duloxetine in the treatment of women with
fibromyalgia with or without major depressive disorder. Pain
2005;119:5–15.
7. Russell IJ, Mease PJ, Smith TR, Kajdasz DK, Wohlreich MM,
Detke MJ, et al. Efficacy and safety of duloxetine for treatment
of fibromyalgia in patients with or without major depressive
disorder: results from a 6-month, randomized, double-blind,
placebo-controlled, fixed-dose trial. Pain 2008;136:432–44.
8. Chappell AS, Bradley LA, Wiltse C, Detke MJ, D’Souza DN,
Spaeth M. A six-month double-blind, placebo-controlled, ran-
domized clinical trial of duloxetine for the treatment of fibro-
myalgia. Int J Gen Med 2008;1:91–102.
9. Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ,
Iyengar S, et al. A double-blind, multicenter trial comparing
duloxetine with placebo in the treatment of fibromyalgia pa-
tients with or without major depressive disorder. Arthritis
Rheum 2004;50:2974–84.
10. Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y.
Milnacipran for the treatment of fibromyalgia in adults: a
15-week, multicenter, randomized, double-blind, placebo-
controlled, multiple-dose clinical trial. Clin Ther 2008;30:
1988–2004.
11. Mease PJ, Clauw DJ, Gendreau RM, Rao SG, Kranzler J,
Chen W, et al. The efficacy and safety of milnacipran for treat-
ment of fibromyalgia: a randomized, double-blind, placebo-
controlled trial. J Rheumatol 2009;36:398–409.
12. Crofford LJ, Mease PJ, Simpson SL, Young JP Jr, Martin SA,
Haig GM, et al. Fibromyalgia relapse evaluation and efficacy
for durability of meaningful relief (FREEDOM): a 6-month,
double-blind, placebo-controlled trial with pregabalin. Pain
2008;136:419–31.
13. Arnold LM, Russell IJ, Diri EW, Duan WR, Young JP Jr,
Sharma U, et al. A 14-week, randomized, double-blinded,
placebo-controlled monotherapy trial of pregabalin in pa-
tients with fibromyalgia. J Pain 2008;9:792–805.
14. Jaeschke R, Singer J, Guyatt GH. Measurement of health
status: ascertaining the minimal clinically important differ-
ence. Control Clin Trials 1989;10:407–15.
15. Beaton DE, Boers M, Wells GA. Many faces of the minimal
clinically important difference (MCID): a literature review
and directions for future research. Curr Opin Rheumatol
2002;14:109–14.
16. Copay AG, Subach BR, Glassman SD, Polly DW Jr, Schuler
TC. Understanding the minimum clinically important dif-
ference: a review of concepts and methods. Spine J 2007;7:
541–6.
17. Wells G, Beaton D, Shea B, Boers M, Simon L, Strand V, et al.
Minimal clinically important differences: review of methods.
J Rheumatol 2001;28:406–12.
18. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS,
Farrar JT, et al. Interpreting the clinical importance of treat-
ment outcomes in chronic pain clinical trials: IMMPACT
recommendations. J Pain 2008;9:105–21.
19. Guy W. ECDEU assessment manual for psychopharmacol-
ogy, revised. US Department of Health, Education, and Wel-
fare publication (ADM). Rockville (MD): National Institute of
Mental Health; 1976. p. 76–338.
20. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C,
Goldenberg DL, et al. The American College of Rheumatology
1990 criteria for the classification of fibromyalgia: report of
the Multicenter Criteria Committee. Arthritis Rheum 1990;33:
160–72.
21. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM.
Clinical importance of changes in chronic pain intensity mea-
sured on an 11-point numerical pain rating scale. Pain 2001;
94:149–58.
22. Demyttenaere K, Bonnewyn A, Bruffaerts R, Brugha T, de
Graaf R, Alonso J. Comorbid painful physical symptoms and
depression: prevalence, work loss, and help seeking. J Affect
Disord 2006;92:185–93.
23. Garcia-Cebrian A, Gandhi P, Demyttenaere K, Peveler R. The
association of depression and painful physical symptoms: a
review of the European literature. Eur Psychiatry 2006;21:
379–88.
24. Jordan K, Dunn KM, Lewis M, Croft P. A minimal clinically
important difference was derived for the Roland-Morris Dis-
ability Questionnaire for low back pain. J Clin Epidemiol
2006;59:45–52.
25. Childs JD, Piva SR, Fritz JM. Responsiveness of the numeric
pain rating scale in patients with low back pain. Spine 2005;
30:1331–4.
26. Cleland JA, Childs JD, Whitman JM. Psychometric properties
of the Neck Disability Index and Numeric Pain Rating Scale in
patients with mechanical neck pain. Arch Phys Med Rehabil
2008;89:69–74.
27. Hagg O, Fritzell P, Nordwall A, for the Swedish Lumbar Spine
Study Group. The clinical importance of changes in outcome
scores after treatment for chronic low back pain. Eur Spine J
2003;12:12–20.
28. Sim J, Jordan K, Lewis M, Hill J, Hay EM, Dziedzic K. Sensi-
tivity to change and internal consistency of the Northwick
Park Neck Pain Questionnaire and derivation of a minimal
clinically important difference. Clin J Pain 2006;22:820–6.
29. Farrar JT, Pritchett YL, Robinson M, Prakash A, Chappell A.
The clinical importance of changes in the 0 to 10 numeric
rating scale for worst, least, and average pain intensity: ana-
lyses of data from clinical trials of duloxetine in pain disor-
ders. J Pain 2010;11:109–18.
30. Perahia DG, Pritchett YL, Desaiah D, Raskin J. Efficacy of
duloxetine in painful symptoms: an analgesis or antidepres-
sant effect? Int Clin Psychopharmacol 2006;21:311–7.
31. Perahia DG, Quail D, Desaiah D, Montejo AL, Schatzberg AF.
Switching to duloxetine in selective serotonin reuptake in-
hibitor non- and partial-responders: effects on painful physi-
cal symptoms of depression. J Psychiatr Res 2009;43:512–8.
32. Tubach F, Ravaud P, Beaton D, Boers M, Bombardier C, Fel-
son DT, et al. Minimal clinically important improvement and
patient acceptable symptom state for subjective outcome mea-
sures in rheumatic disorders. J Rheumatol 2007;34:1188–93.
826 Mease et al
